211. Assessing the economic benefit of robotic and navigational assistance in surgical treatment of L4-L5 spondylolisthesis: is higher upfront equipment cost worth the operative and safety benefits?

Abstract

<h3>BACKGROUND CONTEXT</h3> The use of robotic or navigational guidance has seen tremendous growth in recent years in minimally invasive spine surgery (MISS) due to its ability to reduce operative time, increase patient safety, and aid in surgical accessibility, especially in high incidence pathologies. However, there remain considerable gaps in the literature in regards to the cost-effectiveness of robotic or navigational guidance in the surgical treatment of L4-L5 spondylolisthesis. <h3>PURPOSE</h3> To assess differences in patient outcomes and relative cost effectiveness in L4-L5 spondylolisthesis patients treated using robotic or navigational guidance in MISS procedures. <h3>STUDY DESIGN/SETTING</h3> Retrospective review of prospective MISS database. <h3>PATIENT SAMPLE</h3> A total of 524 MISS patients. <h3>OUTCOME MEASURES</h3> HRQLs, complications, surgical factors. <h3>METHODS</h3> MISS patients with preoperative diagnoses of L4-L5 spondylolisthesis and baseline (BL) and 2-year (2Y) postoperative radiographic/HRQL data were included. Patients were split between those operated on using robotic or navigational guidance (Robotic+) or not (Robotic-). Means comparison analysis assessed differences in radiographic and clinical outcomes at BL, 1Y and 2Y postoperatively. Costs were calculated using the PearlDiver database through estimates from Medicare payscales for services within a 30-day window, including estimates regarding costs of postoperative complications, outpatient healthcare encounters, revisions and medical related readmissions. Quality-adjusted life years (QALYs) was calculated using NDI mapped to SF6D using validated methodology and utilized a 3% discount rate to account for residual decline to life expectancy (78.7 years). <h3>RESULTS</h3> Eighty-eight patients (54.40±12.49 years, 40% female, 30.93±6.52 kg/m², mean CCI: 2.23±1.55) with L4-5 spondylolisthesis were included. At baseline, patients were comparable in age, gender, BMI and CCI (all p>.05). Similarly, patients did not differ significantly in baseline regional nor global radiographic deformity (all p>.05). Perioperatively, Robotic+ patients were significantly less likely to undergo corpectomy (p=.006), and also demonstrated significantly lower EBL (p=.013) and operative time (p=.009). Economic analysis revealed broad cost savings for Robotic+ patients. Specifically, Robotic+ patients demonstrated increased utility gained per QALYs at 1Y (p=.028), as well as Life Expectancy QALYs (p=.002). Furthermore, Robotic+ patients were significantly more likely to demonstrate increased QALYs gained by 2Y (p=.029). Conversely, overall cost per QALY by 2Y was significantly higher for Robotic- patients, which resulted in an approximately 6.5x greater cost per QALY for such patients (76,848 vs 11,839 USD). Overall, Robotic+ patients demonstrated significantly higher cost-effectiveness by 2Y (p<.001). <h3>CONCLUSIONS</h3> Corrective procedures for the treatment of L4-L5 spondylolisthesis and other common spinal pathologies has seen significant growth in the uptake of novel technologies such as robotic or navigational assistance. Though robotic and navigational assistance systems have a significantly higher upfront cost compared to existing techniques, our findings demonstrate reductions in intraoperative invasiveness and OR time pay great dividends in demonstrating the 2Y cost-effectiveness of such novel technologies in minimally-invasive adult spinal deformity surgery. <h3>FDA DEVICE/DRUG STATUS</h3> This abstract does not discuss or include any applicable devices or drugs.